Caption Management’s Emergent Biosolutions EBS Stock Holding History

Caption Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,000	Closed	-$251K	–	1557
2024 Q3	$251K	Buy	+30,000	New	+$273K	﹤0.01%	1037

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Caption Management's EBS Position: Q1 2022 in Review

Caption Management sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 35,300 shares — an estimated $1.53M sold.

Caption Management first reported a position in EBS in Q4 2021 and held it in 1 quarter. The position peaked at $1.53M in Q4 2021. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

Caption Management reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
Caption Management sold 35,300 Emergent Biosolutions shares in Q1 2022, an estimated $1.53M.
Caption Management first reported a position in Emergent Biosolutions in Q4 2021 and held it in 1 quarter.
Caption Management's Emergent Biosolutions position peaked at $1.53M in Q4 2021.
255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Caption Management's 13F filing for Q1 2022, filed 13 May 2022.